Anika Therapeutics (ANIK)
Makes HA-based orthopedic products for OA pain management and regenerative procedures.
Something off on this page? Send us feedback.
Sells Monovisc, Orthovisc, and Cingal for OA pain management, plus Integrity, Hyalofast, and Tactoset for regenerative orthopedics. Revenue is split between OEM relationships and commercial channels, with the United States as the largest market and J&J MedTech central to U.S. Monovisc and Orthovisc.
Develops and manufactures hyaluronic-acid orthopedic products centered on OA pain management and regenerative solutions. Current OA products include Monovisc, Orthovisc, and Cingal; regenerative products include Integrity, Hyalofast, and Tactoset.
Operates through one consolidated segment with OEM and commercial channels. Sales are concentrated in the United States, with additional business in Europe and other international markets.
The business has refocused after selling the Arthrosurface joint-preservation and Parcus sports-medicine assets, returning attention to HA-related products. J&J MedTech is the exclusive U.S. marketer for Monovisc and Orthovisc, Cingal is sold outside the United States, and Hyalofast remains a U.S. pipeline product under FDA review.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 30, 2026 | Barrington | Target | Target: — | Target: $21 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $38.4M · Total debt $23.3M · Total assets $183.5M · Shareholders' equity $137.3M
- Revenue
- $32.6M
- Operating income
- $3.0M
- Net income
- $3.3M
No dividends on record.
| Institutions | ≈ 92.28% | 12.35M shares | |
|---|---|---|---|
| 135 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 5.97% | 799.3K shares | |
| 13 holders · as of Aug 5, 2026 | |||
| Strategic holders | 5.93% | 793.4K shares | |
| 1 holder · as of Oct 17, 2025 | |||
| Adds to | 104.18% | ||
13.38M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 104.18%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Kayne Anderson Rudnick Investment Management LLCInstitution | 11.55% | 1.55M | filed Feb 11, 2021 |
BlackRock, Inc.Institution | 10.83% | 1.45M | as of Jun 30, 2026 |
Caligan Partners LPInstitution | 10.72% | 1.44M | as of Jun 30, 2026 |
BlackRock Portfolio Management LLCStrategic | 5.93% | 793,359 | filed Oct 17, 2025 |
Morgan StanleyInstitution | 4.59% | 614,320 | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 3, 2026 | Gary P. Fischetti | director | +1,000 | $20.75 |
| Aug 4, 2026 | Gary P. Fischetti | director | +1,000 | $20.32 |
| May 1, 2026 | John B. Iii Henneman | director | +5,000 | $14.66 |
| Apr 30, 2026 | Stephen D. Griffin | director, officer: President and CEO | +12,200 | $12.29 |
- Zimmer Biomet
Broad musculoskeletal peer with direct HA knee OA products
- Bioventus
Direct knee OA injection rival through DUROLANE and GELSYN-3
- Sanofi (ADR)
Synvisc franchise competes in knee OA viscosupplementation
- Smith & Nephew (ADR)
Shoulder repair and cartilage-repair peer via REGENETEN and CARTIHEAL
- Pacira BioSciences
Non-opioid knee OA pain rival through ZILRETTA and PCRX-201
- CONMED
Orthopedic soft-tissue repair rival centered on BioBrace
- Stryker
Large sports-medicine peer in rotator cuff repair systems
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Anika Therapeutics | $20.32 | −2.73% | $279.6M | — | 22.8 | 2.3 | +15.6% |
| Zimmer Biomet | $90.69 | −3.50% | $18.18B | 22.9 | 10.4 | 2.1 | +4.8% |
| Bioventus | $13.27 | −2.78% | $924.8M | 17.7 | 16.7 | 1.6 | +3.8% |
| Sanofi (ADR) | $41.64 | −2.06% | $102.08B | 76.0 | — | 1.8 | +11.2% |
| Smith & Nephew (ADR) | $26.94 | −2.05% | $11.55B | 18.8 | — | 1.8 | +4.6% |
| Pacira BioSciences | $24.84 | +0.55% | $971.6M | 70.3 | 8.0 | 1.3 | +6.2% |
| CONMED | $45.74 | −0.93% | $1.38B | 24.9 | 10.2 | 1.0 | +0.3% |
| Stryker | $273.73 | −0.49% | $105.45B | 28.5 | 17.1 | 4.1 | +9.4% |
| Median | 24.9 | 10.4 | 1.8 | +4.8% |